Hepatitis C virus

Hepatitis C virus
Name	Hepatitis C virus
Virus group	IV
Familia	Flaviviridae
Genus	Hepacivirus
Species	Hepatitis C virus
Genome	Positive-sense single-stranded RNA

Hepatitis C virus is a bloodborne RNA virus that primarily infects hepatocytes and causes acute and chronic liver disease, including cirrhosis and hepatocellular carcinoma. First identified in the late 20th century during efforts to characterize non-A, non-B hepatitis, it has major public health significance across World Health Organization regions and has driven advances in antiviral drug development. Research on the virus has involved collaborations among institutions such as the Centers for Disease Control and Prevention, National Institutes of Health, and biotechnology firms in the Silicon Valley and Cambridge, Massachusetts life-sciences cluster.

Virology

Hepatitis C virus is an enveloped, positive-sense single-stranded RNA virus in the family Flaviviridae and genus Hepacivirus. The ~9.6 kb genome encodes a single polyprotein processed by host and viral proteases into structural proteins (Core, E1, E2) and nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, NS5B). Structural studies have leveraged techniques developed at institutions like Cold Spring Harbor Laboratory, Max Planck Institute, and Imperial College London to resolve envelope glycoprotein conformations and receptor interactions. Viral entry depends on host receptors including CD81, scavenger receptor class B type I characterized by research groups at University of California, San Francisco and Karolinska Institutet, and tight junction proteins studied at University of Tokyo. Replication occurs in membranous web structures associated with the endoplasmic reticulum, a process illuminated by cell biology labs at Harvard Medical School, Johns Hopkins University, and ETH Zurich. Genetic heterogeneity yields multiple genotypes and subtypes, a topic advanced by sequencing centers at Wellcome Sanger Institute and Broad Institute.

Transmission and Epidemiology

Transmission is primarily via contact with infectious blood, historically linked to blood transfusion before screening introduced by agencies like U.S. Food and Drug Administration and initiatives in France and Japan. Other routes include injection drug use networks documented in studies from Vancouver, Sydney, and Baltimore, as well as unsafe medical practices reported in parts of Egypt, Pakistan, and Russia. Vertical transmission and sexual transmission are less efficient but have been quantified in cohorts from United Kingdom, Brazil, and South Africa. Global prevalence estimates by World Health Organization and surveillance by European Centre for Disease Prevention and Control show highest burdens in regions affected by historical public health practices and concentrated epidemics in urban centers such as New York City and São Paulo. Outbreak investigations have involved collaboration among public health bodies including Public Health England and the Pan American Health Organization.

Clinical Features and Pathogenesis

Acute infection ranges from asymptomatic to icteric hepatitis, with symptomatic cases described in clinical series from Mayo Clinic, Cleveland Clinic, and Mount Sinai Health System. Approximately 50–85% of infected individuals develop chronic infection leading to fibrosis, cirrhosis, and hepatocellular carcinoma, outcomes characterized in registries at National Cancer Institute and liver centers like King’s College Hospital. Immune-mediated liver injury involves innate and adaptive responses studied by researchers at Salk Institute, Pasteur Institute, and Yale University School of Medicine. Extrahepatic manifestations include mixed cryoglobulinemia, lymphomas, and renal disease, with case series reported by Memorial Sloan Kettering Cancer Center and Stanford University. Co-infections with HIV/AIDS and hepatitis viruses have been focal points for integrated care programs at Johns Hopkins Bloomberg School of Public Health and University of Cape Town.

Diagnosis

Diagnosis relies on serologic and molecular assays developed by diagnostics companies and validated by reference laboratories like Quest Diagnostics, Laboratory Corporation of America, and national reference centers. Initial screening uses anti-HCV antibody tests, with confirmation and viral load quantification by HCV RNA PCR assays standardized by World Health Organization guidelines and implemented in clinical labs at Mayo Clinic Laboratories and Karolinska University Laboratory. Genotyping and sequencing to inform therapy derive from platforms used by Illumina and Thermo Fisher Scientific and are integrated into clinical algorithms at hepatology units such as UCSF Medical Center and Charité – Universitätsmedizin Berlin.

Treatment and Management

Treatment has been revolutionized by direct-acting antiviral (DAA) agents targeting NS3/4A protease, NS5A, and NS5B polymerase, developed in collaborations among biotech firms in Boston, San Francisco, and Basel. Regimens such as sofosbuvir-ledipasvir, glecaprevir-pibrentasvir, and others yield high sustained virologic response rates in trials conducted at University of Pennsylvania, Vanderbilt University Medical Center, and multinational consortia coordinated by World Health Organization. Management of advanced liver disease involves hepatology and transplantation programs at centers like UCLA Health, Hôpital Beaujon, and Toronto General Hospital. International access and pricing issues have prompted policy work by Médecins Sans Frontières and negotiations involving governments of India and South Africa.

Prevention and Control

Prevention strategies include blood screening implemented by national blood services in countries such as United States, Germany, and Australia; harm reduction programs for people who inject drugs promoted by UNODC and UNAIDS; and infection control in healthcare settings exemplified by guidelines from Centers for Disease Control and Prevention and World Health Organization. Vaccine development efforts have involved academic-industry partnerships at National Institutes of Health, Moderna, and research consortia including European Commission–funded projects, though no licensed vaccine exists. Public health elimination initiatives, such as national plans in Georgia and Egypt, combine testing, treatment, and prevention and are monitored by global targets set by World Health Organization.

Category:Viruses